Stock comparison
Genmab A/S
Takeda Pharmaceutical Company Limited
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
GMAB
Genmab A/S
Market cap
$16.5B
Sector
Healthcare
TAK
Takeda Pharmaceutical Company Limited
Market cap
$51.34B
Sector
Healthcare
Overall winner
Genmab A/S GMAB
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | GMAB | TAK | Winner |
|---|---|---|---|
| Warren Buffett | 65C | 44D | GMAB |
| Benjamin Graham | 64C | 56C | GMAB |
| Philip Fisher | 48D | 40D | GMAB |
| Peter Lynch | 25F | 18F | GMAB |
| Joel Greenblatt | 76B | 32F | GMAB |
| Charlie Munger | 68C | 41D | GMAB |
| Terry Smith | 71C | 36D | GMAB |
Side-by-side metrics
| Metric | GMAB | TAK |
|---|---|---|
| Market cap | $16.5B | $51.34B |
| P/E (TTM) | 6.2x | 43.0x |
| EV/EBIT | 12.0x | 22.0x |
| ROIC (TTM) | 43.78% | 2.59% |
| Gross margin | 93.88% | 58.76% |
| Net margin | 18.23% | 4.26% |
| Revenue CAGR 5y | -18.45% | 7.56% |
| EPS CAGR 5y | -23.48% | -3.46% |
| Debt / Equity | 0.1x | 0.6x |
| Dividend yield | 0.0% | 3.79% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
GMAB leads on
- ROIC (TTM)43.78%vs 2.59%+94%
- Debt / Equity0.1xvs 0.6x+88%
- P/E (TTM)6.2xvs 43.0x+86%
- Net margin18.23%vs 4.26%+77%
TAK leads on
- Revenue CAGR 5y7.56%vs -18.45%+141%
- Dividend yield3.79%vs 0.0%+100%
- EPS CAGR 5y-3.46%vs -23.48%+85%
- Market cap$51.34Bvs $16.5B+68%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.